Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

about

Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis.Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis.

P2860

Q52716546-EB45AEF5-00A0-4E7A-AF98-3C972026458B Q55114038-58EAA4A1-5D48-43CF-B5D7-BCDBBDD8C931

P2860

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

Item

http://www.wikidata.org/entity/Q41151927

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

@en

type

Item

label

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

@en

prefLabel

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

@en

P1476

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

@en

P2093

Amy Hajari Case

http://www.w3.org/2001/XMLSchema#string

Peace Johnson

http://www.w3.org/2001/XMLSchema#string

P2860

Pulmonary rehabilitation for interstitial lung disease

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Oxygen therapy for interstitial lung disease: a systematic review.

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

Adverse effects of anticancer agents that target the VEGF pathway.

P304

e000192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJRESP-2017-000192

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28883926

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

5531305

http://www.w3.org/2001/XMLSchema#string

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

about

P2860

P2860

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932